

Piero Colombatto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4990352/publications.pdf>

Version: 2024-02-01

49
papers

1,908
citations

361045

20
h-index

243296

44
g-index

50
all docs

50
docs citations

50
times ranked

2316
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatitis B Surface Antigen Serum Levels Help to Distinguish Active From Inactive Hepatitis B Virus Genotype D Carriers. <i>Gastroenterology</i> , 2010, 139, 483-490.	0.6	361
2	Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. <i>Journal of Hepatology</i> , 2002, 36, 263-270.	1.8	290
3	Association of hepatitis C virus envelope proteins with exosomes. <i>European Journal of Immunology</i> , 2004, 34, 2834-2842.	1.6	178
4	Hepatitis C virus infection in Italian patients with oral lichen planus: a prospective case-control study. <i>Journal of Oral Pathology and Medicine</i> , 1996, 25, 527-533.	1.4	158
5	Liver stiffness in the hepatitis B virus carrier: A non-invasive marker of liver disease influenced by the pattern of transaminases. <i>World Journal of Gastroenterology</i> , 2008, 14, 6154.	1.4	116
6	Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors. <i>Journal of Hepatology</i> , 2005, 42, 61-67.	1.8	97
7	Long term outcome of inactive and active, low viraemic HBsAg negative hepatitis B virus infection: Benign course towards HBsAg clearance. <i>Liver International</i> , 2017, 37, 1622-1631.	1.9	51
8	Long Term Response to Therapy of Chronic Anti-HBe Positive Hepatitis B Is Poor Independent of Type and Schedule of Interferon. <i>American Journal of Gastroenterology</i> , 1999, 94, 1366-1372.	0.2	50
9	Long term response to therapy of chronic anti-HBe positive Hepatitis B is poor independent of type and schedule of interferon. <i>American Journal of Gastroenterology</i> , 1999, 94, 1366-1372.	0.2	48
10	A Multiphase Model of the Dynamics of HBV Infection in Hbeag-Negative Patients during Pegylated Interferon- α 2A, Lamivudine and Combination Therapy. <i>Antiviral Therapy</i> , 2006, 11, 197-212.	0.6	46
11	Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease. <i>PLoS ONE</i> , 2015, 10, e0130209.	1.1	45
12	A Serum MicroRNA Signature Is Associated with the Immune Control of Chronic Hepatitis B Virus Infection. <i>PLoS ONE</i> , 2014, 9, e110782.	1.1	41
13	Quantitative analysis of IgM anti-HBc in chronic hepatitis B patients using a new gray-zone for the evaluation of borderline values. <i>Journal of Hepatology</i> , 1996, 25, 644-648.	1.8	39
14	Identification of New Autoantigens by Protein Array Indicates a Role for IL4 Neutralization in Autoimmune Hepatitis. <i>Molecular and Cellular Proteomics</i> , 2012, 11, 1885-1897.	2.5	38
15	Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon. <i>Journal of Hepatology</i> , 2003, 39, 164-167.	1.8	34
16	Viral load 1 week after liver transplantation, donor age and rejections correlate with the outcome of recurrent hepatitis C. <i>Liver International</i> , 2007, 27, 612-619.	1.9	30
17	Sustained Response to Interferon-Ribavirin Combination Therapy Predicted by a Model of Hepatitis C Virus Dynamics Using Both Hcv Rna and Alanine Aminotransferase. <i>Antiviral Therapy</i> , 2003, 8, 519-530.	0.6	29
18	Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?. <i>Journal of Hepatology</i> , 2018, 68, 597-600.	1.8	28

#	ARTICLE	IF	CITATIONS
19	Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B. <i>Journal of Infection</i> , 2013, 67, 322-328.	1.7	26
20	A Novel Immunosuppressive Strategy Combined with Preemptive Antiviral Therapy Improves the Eighteen-Month Mortality in HCV Recipients Transplanted with Aged Livers. <i>Transplantation</i> , 2008, 86, 1666-1671.	0.5	22
21	Minor-but-Complex Liver Resection. <i>Medicine (United States)</i> , 2015, 94, e1188.	0.4	19
22	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. <i>Digestive and Liver Disease</i> , 2017, 49, 731-741.	0.4	19
23	Bio-mathematical models of viral dynamics to tailor antiviral therapy in chronic viral hepatitis. <i>World Journal of Gastroenterology</i> , 2009, 15, 531.	1.4	19
24	High prevalence of G1 and G2 TT-virus infection in subjects with high and low blood exposure risk: identification of G4 isolates in Italy. <i>Journal of Hepatology</i> , 1999, 31, 990-996.	1.8	15
25	A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy. <i>Antiviral Therapy</i> , 2006, 11, 197-212.	0.6	15
26	Techniques of parenchyma-sparing hepatectomy for the treatment of tumors involving the hepatocaval confluence: A reliable way to assure an adequate future liver remnant volume. <i>Surgery</i> , 2017, 162, 483-499.	1.0	13
27	Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase. <i>Antiviral Therapy</i> , 2003, 8, 519-30.	0.6	11
28	HBV pre-core mutant in genotype D infected children is selected during HBeAg/anti-HBe seroconversion and leads to HBeAg negative chronic hepatitis B in adulthood. <i>Journal of Medical Virology</i> , 2018, 90, 1232-1239.	2.5	8
29	Real life experiences in HCV management in 2018. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 117-128.	2.0	8
30	Do the circulating Pre-S/S quasispecies influence hepatitis B virus surface antigen levels in the HBeAg negative phase of HBV infection?. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1406-1416.	1.9	6
31	Management and Treatment of Patients with Chronic Hepatitis B: Towards Personalized Medicine. <i>Viruses</i> , 2022, 14, 701.	1.5	6
32	The prevalence of hepatitis C virus types in patients of the same geographic area, according to the source of infection and liver disease. <i>Clinical and Diagnostic Virology</i> , 1997, 8, 189-194.	1.8	5
33	Personalized therapy in chronic viral hepatitis. <i>Molecular Aspects of Medicine</i> , 2008, 29, 103-111.	2.7	5
34	A cost-effectiveness model to personalize antiviral therapy in naive patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2015, 47, 249-254.	0.4	5
35	A single staggered dose of calcineurin inhibitor may be associated with neurotoxicity and nephrotoxicity immediately after liver transplantation. <i>Clinical Transplantation</i> , 2009, 23, 853-860.	0.8	4
36	Optimization of in vitro HBV replication and HBsAg production in HuH7 cell line. <i>Journal of Virological Methods</i> , 2013, 189, 110-117.	1.0	4

#	ARTICLE	IF	CITATIONS
37	PTFE Graft as a "Bridge" to Communicating Veins Maturation in the Treatment of an Intrahepatic Cholangiocarcinoma Involving the 3 Hepatic Veins. The Minor-but-Complex Liver Resection. <i>Annals of Surgical Oncology</i> , 2016, 23, 911-911.	0.7	3
38	Epidemiological, demographic and clinical data on chronic viral hepatitis C in Tuscany. <i>Current Medical Research and Opinion</i> , 2019, 35, 661-666.	0.9	3
39	Modeling Hepatocellular Carcinoma Cells Dynamics by Serological and Imaging Biomarkers to Explain the Different Responses to Sorafenib and Regorafenib. <i>Cancers</i> , 2021, 13, 2064.	1.7	3
40	Clinical epidemiology of chronic viral hepatitis B: A Tuscany real-word large-scale cohort study. <i>World Journal of Hepatology</i> , 2018, 10, 409-416.	0.8	3
41	Upper transversal hepatectomy with double hepatic vein resection and reconstruction to treat colorectal cancer liver metastases at the hepatocaval confluence: a strategy to achieve R0 liver-sparing resection. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 1741-1750.	0.8	3
42	Oral administration of gentamicin for prophylaxis of KPC-producing <i>Klebsiella pneumoniae</i> gut colonization in patients treated with a novel parenchymal-sparing liver surgery: the GEN Gut study. <i>Intensive Care Medicine</i> , 2016, 42, 124-125.	3.9	2
43	Sustained Virological Response in HCV Patients Treated with Daclatasvir+Sofosbuvir, with or without Ribavirin: A Multicenter, Field-Practice Experience. <i>Gastroenterology</i> , 2017, 152, S1097.	0.6	1
44	Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 1406.	1.0	1
45	Outcome of chronic anti-HBe positive hepatitis B. <i>Digestive and Liver Disease</i> , 2000, 32, A131.	0.4	0
46	Hepatitis C virus infection: early diagnosis and identification of response to antiviral therapy. <i>Expert Review of Molecular Diagnostics</i> , 2001, 1, 310-314.	1.5	0
47	The early decrease of hepatitis C virus core antigen in the serum of chronic hepatitis C patients predicts drug efficacy and primary response to antiviral therapy. <i>Journal of Hepatology</i> , 2002, 36, 104.	1.8	0
48	Modeling the Dynamics of HCV Infected Cells to Tailor Antiviral Therapy in Clinical Practice: Can This Approach Fit for Neoplastic Cells?. <i>SIMAI Springer Series</i> , 2012, , 329-336.	0.4	0
49	Modeling HCV Dynamics in Clinical Practice to Personalize Antiviral Therapy. , 2016, , 303-321.		0